Baird downgraded ResMed (RMD) to Neutral from Outperform with a price target of $275, down from $300. The firm adjusted ratings and medical technology as part of its 2026 outlook. It cites “waning visibility” into ResMed’s earnings and revenue along with increasing headline-risk around competitor expansion for the downgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed receives FDA clearance for PTCS to be marketed as Smart Comfort
- Resmed’s Strategic Positioning and Market Valuation Suggest 19% Upside Despite Future CMS Challenges
- ResMed removed from APAC Conviction List at Goldman Sachs
- ResMed Streamlines Governance at Annual Meeting
- ResMed price target lowered to $300 from $320 at Baird